# Serum BDNF levels as a potential prognostic marker for functional recovery in stroke: Preliminary findings from a prospective observational study

**Authors:** Seyoung Shin, Heegoo Kim, Dae Hyun Kim, Won Hyuk Chang

PMC · DOI: 10.1371/journal.pone.0343929 · PLOS One · 2026-02-27

## TL;DR

This study explores whether blood levels of BDNF and MMP-9 can predict recovery after stroke, but finds no strong independent predictive power.

## Contribution

The study provides preliminary insights into the longitudinal changes of BDNF and MMP-9 in stroke patients and their potential biological relevance.

## Key findings

- Mature BDNF levels decreased significantly over time after stroke.
- MMP-9 levels declined consistently across all timepoints.
- Baseline functional scores were the strongest predictors of recovery outcomes.

## Abstract

Brain-derived neurotrophic factor (BDNF) crosses the blood-brain barrier and may serve as a marker of neuroplasticity. This study evaluated whether serum levels of mature BDNF, proBDNF, and matrix metalloproteinase-9 (MMP-9) can predict functional recovery after stroke. In this prospective observational study, 93 patients with unilateral stroke and motor impairment were recruited. Clinical, and demographic data, as well as serum levels of mature BDNF, proBDNF, and MMP-9 were collected. Functional assessments measuring stroke severity, cognition, motor function, balance, and mood were conducted at three timepoints: after acute care (T0), 2 weeks post-rehabilitation (T1), and 3 months post-onset (T2). Mature BDNF significantly decreased from T0 to T2 (p = 0.003), while proBDNF remained stable. MMP-9 declined consistently across timepoints (p < 0.001). MMP-9 levels at baseline differed by BDNF genotype (p < 0.05). However, none of the biomarkers independently predicted functional recovery. Functional outcomes improved significantly over time (p < 0.001), with baseline functional scores being the strongest predictors at T1 and T2. Although these biomarkers were not independent predictors of recovery, their longitudinal trajectories may reflect underlying neurobiological recovery mechanisms during rehabilitation, although their prognostic utility remains inconclusive.

## Linked entities

- **Proteins:** BDNF (brain derived neurotrophic factor), MMP9 (matrix metallopeptidase 9)
- **Diseases:** stroke (MONDO:0005098)

## Full-text entities

- **Genes:** MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, BBS2 (Bardet-Biedl syndrome 2) [NCBI Gene 583] {aka BBS, RP74}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** brain injury (MESH:D001930), hypertension (MESH:D006973), ischemic stroke (MESH:D002544), Depression (MESH:D003866), infarct (MESH:D007238), liver, kidney, cardiac, or pulmonary disease (MESH:D006331), motor (MESH:D000068079), inflammatory (MESH:D007249), neurodegenerative diseases (MESH:D019636), NIHSS (MESH:C538175), neurotoxic (MESH:D020258), neurological or psychiatric diseases (MESH:D001523), cerebral ischemia (MESH:D002545), traumatic brain injury (MESH:D000070642), hemorrhagic stroke (MESH:D000083302), brain edema (MESH:D001929), Stroke (MESH:D020521), ischemic small vessel disease (MESH:D059345), ischemia (MESH:D007511)
- **Chemicals:** chloroform (MESH:D002725), alcohol (MESH:D000438), ethylenediaminetetraacetic acid (MESH:D004492), phenol (MESH:D019800)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G-to-A, Met/Met, Val/Val, Val/Met, Val66Met

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948131/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948131/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948131/full.md

---
Source: https://tomesphere.com/paper/PMC12948131